Next-Generation, Reusable Respirators

Canopy is an in-market occupational safety company focused on sustainable solutions that protect the world’s well-being. Our team of scientists, industrial designers, and healthcare industry professionals came together to design a solution for our frontline workers and individual consumers. The Canopy is an award-winning, transparent barrier face covering, engineered with the utmost comfort, safety, and performance in mind.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$18,397.46 Raised


Reasons Icon

Canopy is creating the next generation of protective respirator masks for the world’s 59 million healthcare workers, and individuals seeking an alternative to disposable N95s. The company is well-positioned to capture a meaningful share of the market for N95s, which is expected to reach $5.7B by 2030.*

Reasons Icon

In October 2022, the Biden administration announced the National Biodefense Strategy & Implementation Plan, which highlighted the need to “invest in and incentivize innovations in PPE design, novel material development, advanced manufacturing, and reusable technology capabilities” for domestic PPE production & supply. With early traction and Canopy’s production capabilities already in place, the company views this as national-level evidence of future market opportunity.**

Reasons Icon

The Canopy team brings together leading angel investors, entrepreneurs, scientists, engineers, designers, clinicians, hospital administrators. Canopy’s founders were also recently accepted into the Fall 2021 cohort of StartX, the network for the top 10% of Stanford’s startups.

*Information provided by the National Library of Medicine, Grand View Research, and The Synergist (sourcesourcesource)

**For more info about the National Biodefense Strategy & Implementation Plan, visit (source)

**Quote referenced can be found on page 29, section 3.3.2 (source)

Providing Professionals & Consumers With the Next Generation of High Performance PPE 

When protecting ourselves and the people we love from fast-spreading illness, wildfire smoke, and poor air quality, respirator masks are a valuable resource. Yet, in 2020, Canopy was founded on the premise that existing respirator options were in need of innovation.

In an effort to create something better – and ultimately more sustainable – our team of Johns Hopkins-trained biomedical engineers and former Nike industrial designers has developed a new kind of reusable respirator mask. Canopy’s sophisticated design combines patented filter technology, with a patient-friendly, anti-fog, transparent front, and is able to be produced on a mass-scale for rapid distribution and deployment.

The Problem & Our Solution

Reimagining Frontline Protection to Reduce Waste & Improve Safety, Sustainability and Emergency Preparedness

Each day, healthcare professionals and frontline workers require personal protective equipment (PPE) in order to safeguard themselves while serving others. Disposable N95 respirators are considered the standard, yet their design presents many challenges in terms of comfort, communication, and breathability. These devices create over 7,200 tons of landfill waste each day. Additionally, the United States is still not equipped to prevent another PPE shortage.*

*USG has solicited proposals to preserve domestic industrial base capacity to surge to 100M disposable N95s/mo. 

The issue is that in a pandemic, demand is between 540M and 1.2B per month, for healthcare alone. 

A more sustainable alternative is needed, and the Biden administration agrees. In October 2022, the National Biodefense Strategy & Implementation Plan was announced to address pandemic preparedness capabilities. One of the plan's pillars includes the push to "invest in and incentivize innovations in PPE design, novel material development, advanced manufacturing, and reusable technology capabilities that result in steady state and surge capacities for domestic production of PPE with resilient supply chains and enhanced effectiveness, usability, comfort, affordability, reusability, and fit capabilities to protect against various routes of pathogen transmission, including for use by the general population." This national support for innovative health & safety resources creates a unique landscape for Canopy.*

*For more info about the National Biodefense Strategy & Implementation Plan, visit (source)

*Quote referenced can be found on page 29, section 3.3.2 (source)

Aimed at solving these shortcomings, Canopy’s patented respirator system offers a highly durable extended-use filter, along with proprietary hardware that is easy to clean. It features a soft but snug silicone face seal for preventing skin abrasions, as well as a transparent design that enables communication, including lip-reading and smiling. In independent studies and testing by the National Institute for Occupational Safety & Health (NIOSH), Canopy exceeds federal N95 standards for filtration, breathability and fit. Most importantly, it can be reused for up to a year, facilitating a 98% waste reduction compared to disposable masks. 

The Market & Our Traction

Patented Product, National Recognition, 4.5 / 5 Star User Reviews, & a Large Global Market

In November 2021, a poll conducted by NIOSH leadership found that the average hospital requested approximately 4,000 reusable respirators for its staff. With 6,093 hospitals in the U.S. alone, this equates to a market opportunity of 24.3M units. Meanwhile, beyond the healthcare sector, Canopy aims to partner with multiple government agencies to support the national stockpile, Department of Defense, and Veterans Affairs Hospital Networks. 

(source, source, source)

Understanding that there is a sizable demand for our product across multiple industries and within the direct-to-consumer market, Canopy has worked heads down to complete design, tooling, and validation testing. We’ve also executed production runs and signed multi-year agreements with some of the world’s largest medical manufacturers.

In 2021, Canopy obtained a utility patent for the company’s filter design and has additionally filed for PCT protection. As the company works to secure full regulatory certification with NIOSH, we continue to amass proof positive testimonials for our product, and have won numerous innovation awards in the process. Based on our traction, we feel confident that we will be one of the world’s first startups to achieve this certification, and are well on our way to becoming a trusted industry leader.

*These testimonials may not be representative of the experience of other customers and are not a guarantee of future performance or success.

Why Invest

Join Leading Angel Investors & Entrepreneurs to Help Us Protect the World's Well-Being

Increasingly, government reports, such as the White House’s recent 2022 National COVID-19 Preparedness Plan, are calling for investment in respiratory protective devices as a critical countermeasure against the next viral outbreak or biological threat. As a company, Canopy’s goal is to not only meet the demand for sustainable solutions, but also to protect the world’s well-being by innovating respirator technology.

Having previously raised $2.2M in funding from leading entrepreneurs and angel investors, we’ve been able to establish a strong foothold in the DTC market, and now we’re ready to expand and become certified to serve our B2B market of hospitals and the healthcare industry at large. Help us see our mission through, by investing in Canopy today! 

Code View


282 Katonah Avenue #537
Katonah, NY 10536

Canopy is an in-market occupational safety company focused on sustainable solutions that protect the world’s well-being. Our team of scientists, industrial designers, and healthcare industry professionals came together to design a solution for our frontline workers and individual consumers. The Canopy is an award-winning, transparent barrier face covering, engineered with the utmost comfort, safety, and performance in mind.


Joe Rosenberg
Joe Rosenberg
Founder and President

From 2010-2018, Joe was a founding team member of Google Shopping Actions, the company’s expansion into verticalized search for retail. He focused on partnership development and management with the country’s largest retailers and fintech providers to implement shared omni-channel distribution strategies in an effort to mitigate Amazon’s market dominance. Joe has an uncanny ability to inspire and motivate partners, clients and team members alike with his cutting-edge ideas and approaches to business development implementing change at large institutions.

Joe has structured first-of-their-kind partnership deals between Google and organizations in both the retail and financial services industries, including negotiating agreements impacting more than $1B of Google e-commerce transaction volume.

Joe left Google in 2018 to pursue entrepreneurial endeavors. He is the co-founder of Subject to Change Wine Company, a globally distributed natural winery based in California. He earned a BA with honors from the Gallatin School at NYU in 2010.

Kim Rosenberg
Kim Rosenberg
Founder and CEO

Prior to Canopy, Kim led Apollo Global Management's $20B high growth Pension Risk Transfer (PRT) business for its insurance unit, Athene. Kim had P&L accountability and oversight of all key functions.

During her tenure, Kim took the business to number one in the market, writing a record $5.5B of new business in 2020.

Kim structured and closed several landmark transactions, including with GE ($2B) and JCPenney ($3.2B). Kim also sat on the board of the women’s Employee Resource Group (ERG) as a Diversity, Equity & Inclusion leader, and as a sponsor of underrepresented talent.

Prior to joining Athene, Kim was one of four founders of $1.2 trillion asset manager Legal and General Group’s US PRT business where she served as Head of Distribution since its 2015 market launch. Kim led sales, marketing, client solutions, business strategy and leadership development growing the business to nearly $4 billion in assets and 50 employees within five years. She previously served as Deputy Head of Distribution for Legal & General Investment Management America business where she worked with corporate pension and insurance clients to implement liability-driven investment and fixed income strategies. Her leadership contributed to nearly $50B of asset growth during her tenure.

Prior to Legal & General, Kim started her career at MBIA Asset Management. Her final role was as a Director where she led the development of pension de-risking strategies and insurance solutions for institutional clients. Prior she helped guide MBIA through the financial crisis, then pivot the business to a retirement solutions platform. Pre-financial crisis she led asset/liability risk management for a $30B bespoke lending business.

Kim holds a Bachelor of Business Administration in public accounting and an honors degree from the Pforzheimer Honors College at Pace University where she graduated magna cum laude. She also holds a Master of Business Administration from Marist College.

QX Yee

QX Yee

Product development consultant

A Singapore native, QX was awarded the prestigious Defense Science and Technology Scholarship in 2009by the Singapore government. After graduating with top honors in 2013 from Johns Hopkins University with a B.S in Biomedical Engineering and MSE in bioengineering Innovation and Design, QX returned to Singapore to work at DSO National Laboratories, Singapore's national defense research lab.

During his 6-year tenure at DSO, QX specialized in soldier performance, developing products such as the patented A-Lite backpack, which reduced soldier fatigue by properly distributing heavy loads. The backpack received the company's Innovation Award and is currently a standard issue for the Singapore Army. QX’s team drove DSO’s product development strategy. For his work in shaping the workflow and user interface for the Xentinel counter-drone vehicle, QX was awarded the KINETIC award, the company’s highest internal award. QX also lead the DSO ModSquad, an all-volunteer team providing solutions for the disabled and less fortunate. Under QX’sleadership, the Mod Squad designed and delivered a toy to teach music and rhythm to young children with cerebral palsy and other developmental disorders.

In addition to his role at Canopy, QX is the proprietorof Ascent Bikes, a high-performance bicycle company.

Lisa Brosseau, ScD,  CIH

Lisa Brosseau, ScD, CIH

Industrial Hygiene Consultant

Dr. Brosseau is among the world’s most cited scholar on Respiratory Protection. She is a consultant to the National Institute of Occupational Safety and Health (NIOSH) and the University of Minnesota Center for Infectious Disease Research and Policy (CIDRAP). Past clients have included 3M, Ontario Nurses Union, Manitoba Nurses Union, UAW, National Education Association, OSHA, Moldex, TSI, Inc., and the CDC.

Lisa is certified by the American Board of Industrial Hygiene and Associate Faculty of Occupational Hygiene in the British Occupational Hygiene Society with a focus on respiratory protection, aerosol measurement, filtration performance, and small business health and safety.

Dr. Elizabeth Clayborne, MD, MA

Dr. Elizabeth Clayborne, MD, MA

Clinical Advisor

Dr. Clayborne attended Duke University as an undergraduate where she designed her own major in Medical Ethics and Religion. Prior to medical school she completed a two-year research fellowship at National Institutes of Health in the Social and Behavioral Research Branch of the National Human Genome Research Institute with a research focus on race, ethnicity and genetics. Dr. Clayborne attended to medical school at Case Western Reserve University where she completed a dual MD/MA Bioethics degree in 4 years. 

She went on to complete residency in Emergency Medicine at the George Washington University Hospital and served as Chief Resident in her fourth year. Dr. Clayborne is currently a faculty member at the University of Maryland School of Medicine Department of Emergency Medicine with an academic focus on ethics, health policy, end of life care, health disparities and innovation/entrepreneurship. She developed a novel epistaxis device as a resident and in 2015 was awarded the NSF I-Corps grant which helped to launch her company Emergency Medical Innovation, LLC. She is the former Chair of the MedChi Committee on Ethics and Judicial Affairs, serves on the Ethics Committee of the American College of Emergency Physicians and is an active member of the Society of Academic Emergency Medicine, the American Medical Association and the National Medical Association

Tom Gsell, PhD

Tom Gsell, PhD

Filtration Consultant

Over a span of 36 years, Tom helped grow Pall Corporation into a lead innovator in the field of high-tech filtration. He held R&D leadership positions in increasing responsibility, and appointment to Senior Corporate Vice President in 1996. 

Tom’s career led to senior level management responsibilities including global leadership of Materials R&D for both the Pall Industrial and Life Sciences (Medical) divisions. During his tenure Pall’s revenues and profits grew rapidly, fueled by new product innovation made in part possible by the teams under Tom’s purview. 

Tom is named as a co-inventor on approximately hundreds granted and published US and International patents, as well as a number of peer reviewed scientific publications. 

Dr. Narissa Joyner, MD

Dr. Narissa Joyner, MD

Clinical Advisor

Dr. Joyner is an attending physician in Emergency Medicine at Lenox Hill Hospital in New York City. She completed her training in emergency medicine at Morristown Medical Center Regional Trauma Center in Morristown, NJ. Upon board certification in emergency medicine, she began her independent career with Northwell Health. Dr. Joyner serves on the Board of Governors for Physician Partners at Northwell Health and is an active member of the American College of Emergency Physicians, the Society of Academic Emergency Medicine, the American Medical Association, the National Medical Association and the Medical Society of the State of New York- Young Physician Section. She is a clinical advisor to Canopy, having served on the front lines of the COVID-19 Pandemic at Lenox Hill Hospital for its duration. Dr. Joyner provides product development guidance and clinical feedback to Canopy, and has been instrumental in creating a clinical advisory group for Canopy’s product development.

David Narrow

David Narrow


David Narrow is co-founder and CEO of Sonavex Inc., a venture-backed commercial stage medical device company spun-out of Johns Hopkins University, which has raised over $14M. The company develops and commercializes ultrasound products for surgeons, including a technology for detecting post-operative vascular complications. 

David previously worked with multinational medical device companies to commercialize their technologies and provide long-term business strategy as a healthcare consultant at Health Advances LLC. Narrow earned his B.S. in Biomedical Engineering with Highest Distinction from the University of Rochester before receiving his Masters from Johns Hopkins University. He was named 30 Under 30 in Healthcare by Forbes in 2016, 40 Under 40 by the Baltimore Business Journal in 2017, and recognized as Baltimore’s Top BioHealth Startup CEO in 2019.

Governor Peter Shumlin

Governor Peter Shumlin


Governor Peter Shumlin served three terms as the 81st governor of the state of Vermont. He was a member of the Vermont House of Representatives from 1990 to 1993, and served as State Senator for the Windham County from 1993 to 2003 and from 2007 to 2011, and he was elected president of the senate for 10 of those years. Shumlin served as the chair of the Democratic Governors Association during his first two terms.

During his time in office, Governor Shumlin established Vermont as a leader on progressive policies, making the state the first to guarantee universal pre-kindergarten education for all 3 and 4-year-old children, pass a mandatory GMO labeling law, and achieve near universal healthcare coverage with the lowest rate of uninsured in the country. Under his leadership, Vermont consistently ranked among the top states in solar energy jobs per capita and enacted a number of laws to boost renewable energy production and combat climate change. Because of Vermont’s leadership, Governor Shumlin was invited by President Obama to the Paris Climate Summit to push for a global climate agreement.

Governor Shumlin turned the nation’s eyes to the problem of opiate and heroin addiction by dedicating his entire 2014 State of the State Address to the issue and pushing for policies to treat addiction as the healthcare crisis that it is.

A committed entrepreneur, Shumlin is the longtime co-director of Putney Student Travel, National Geographic Student Expeditions, and Smithsonian Student Travel, sending high school age students on educational programs and service projects across the globe. He is a Director of The Scotts-MiracleGro Company, has served as a visiting fellow at the Harvard Kennedy School of Government, and has taught at the Harvard Chan School of Public Health as the Menschel Senior Leadership Fellow.

Kwame Ulmer

Kwame Ulmer

Regulatory Consultant

Mr. Ulmer led Regulatory Affairs and Quality Assurance for Danaher Corporation. Prior to that he spent 12 lears at the FDA, retiring as Deputy Director. He has reviewed over 1,000 new medical devices and technologies.

Kwame holds a Masters in Materials Engineering and a MBA from University of Virginia.

Dale Pfreim

Dale Pfreim

Regulatory Consultant

- President, ICS Laboratories

- Clients include 3M, MSA, GVS, US Army


Mar 30, 2023
Class CF Common Units

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income





Grove Biomedical LLC

Corporate Address


282 Katonah Avenue #537, Katonah, NY 10536

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Class CF Common Units

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



*Maximum Number of Units Offered subject to adjustment for bonus units. See Bonus info below.

Investment Incentives and Bonuses*


Friends and Family Early Birds

Invest $250 or more within the first 48 hours of the initial offering date and receive 30% bonus units

Super Early Bird Bonus

Invest $250 or more within the first week of the initial offering date and receive 20% bonus units

Early Bird Bonus

Invest $250 or more within the first two weeks of the initial offering date and receive 10% bonus units


$500+ | Tier 1

Invest $500+ and receive 25% off a Canopy respirator + 5% Bonus Units.

$1,000+ | Tier 2

Invest $1000+ and receive 50% off a Canopy respirator + 10% Bonus Units. 

$2,500+ | Tier 3

Invest $2500+ and receive a free Canopy respirator + 10% Bonus Units.

$5,000+ | Tier 4

Invest $5000+ and receive two free Canopy respirators + 15% Bonus Units.

$10,000+ | Tier 5

Invest $10000+ and receive two free Canopy respirators, 20% Bonus Units, and a private meeting with Canopy’s founders.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus units from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Grove Biomedical, LLC will offer 10% additional bonus units for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine members will receive a 10% bonus for any units they purchase in this offering. For example, if you buy 100 units of Class CF Units at $5.56 / unit, you will receive 10 additional units of Class CF Units, meaning you'll own 110 units for $556. Fractional units will not be distributed and unit bonuses will be determined by rounding down to the nearest whole unit.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned time-based or amount-based bonuses.


Article Image
Katonah Lewisboro Times

Waccabuc Neighbors Look to Reinvent N95 Respirators

Article Image
Fast Company

World Changing Ideas Awards 2021: Pandemic Response Finalists and Honorable Mentions

Article Image
Nonwovens Industry

Canopy Respirator Wins RISE Innovation Award

Article Image
Fast Company

See the most innovative designs of 2022

Article Image
Plastics Today

Eastman’s Tritan Co-Polyester Brings Clear Advantage to New Medical Applications

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Canopy.


StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.


Tier 1

Invest $500+ and receive 25% off a Canopy respirator + 5% Bonus Units.


Tier 2

Invest $1000+ and receive 50% off a Canopy respirator + 10% Bonus Units.


Tier 3

Invest $2500+ and receive a free Canopy respirator + 10% Bonus Units.


Tier 4

Invest $5000+ and receive two free Canopy respirators + 15% Bonus Units.


Tier 5

Invest $10000+ and receive two free Canopy respirators, 20% Bonus Units, and a private meeting with Canopy’s founders.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.